» Articles » PMID: 24118636

Protection Against Hepatitis E Virus Infection by Naturally Acquired and Vaccine-induced Immunity

Overview
Publisher Elsevier
Date 2013 Oct 15
PMID 24118636
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Immunity acquired from infection or vaccination protects humans from symptomatic hepatitis E. However, whether the risk of hepatitis E virus (HEV) infection is reduced by the immunity remains unknown. To understand this issue, a cohort with 12 409 participants randomized to receive the hepatitis E vaccine Hecolin(®) or placebo were serologically followed up for 2 years after vaccination. About half (47%) of participants were initially seropositive. A total of 139 infection episodes, evidenced by four-fold or greater rise of anti-HEV level or positive seroconversion, occurred in participants who received three doses of treatment. Risk of infection was highest among the baseline seronegative placebo group participants (2.04%). Pre-existing immunity and vaccine-induced immunity lower the risk significantly, to 0.52% and 0.30%, respectively. In conclusion, both vaccine-induced and naturally acquired immunity can effectively protect against HEV infection.

Citing Articles

Immunogenicity, Efficacy, and Effectiveness of Two-Dose and Shorter Schedules of Hepatitis E Vaccine: A Systematic Review.

Azam B, Marti M, Goel A, Aggarwal R Vaccines (Basel). 2025; 13(1).

PMID: 39852808 PMC: 11768984. DOI: 10.3390/vaccines13010028.


Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.

Zhang L, Zhang Q, Liu J, Wu W, Jiang Z, Yan B Hum Vaccin Immunother. 2025; 21(1):2448882.

PMID: 39797410 PMC: 11730616. DOI: 10.1080/21645515.2024.2448882.


Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus.

Zhu K, Liao M, Chen L, Lu J, Huang X, Zhuang C NPJ Vaccines. 2024; 9(1):245.

PMID: 39702395 PMC: 11659514. DOI: 10.1038/s41541-024-01041-5.


Epidemiological Characteristics and Spatiotemporal Clustering of Symptomatic Hepatitis E Virus Reinfection in Zhejiang Province, 2005-2023.

Zhou L, Chen Y, Wang F, Chen Z, Lu Y, Miao Z Viruses. 2024; 16(11).

PMID: 39599790 PMC: 11599083. DOI: 10.3390/v16111676.


A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults.

Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J J Infect Dis. 2024; 230(5):1093-1101.

PMID: 38536442 PMC: 11565884. DOI: 10.1093/infdis/jiae148.